It has been one year since Verily became an Alphabet company, but we’re building on a legacy that extends much further back. From inception, our mission has been to deploy our technology and expertise into the field of healthcare to help improve people’s lives. We’re doing this by developing platforms and tools that help gather, organize, and understand health information so that it is useful and actionable. Together with our partners, we're hopeful that these platforms and tools will result in better prevention and management of health conditions in the future.
We recognize that no company acting alone can affect major change in healthcare and so our approach is to partner with leading life sciences companies, government organizations, health systems, and patient advocacy groups with deep domain expertise. Our partners help shape and inform our projects and add speed, precision, and scale to our efforts.
We're early in our journey, but have entered into several exciting partnerships and joint ventures that advance our mission:
- An ongoing collaboration with Dexcom to develop miniaturized, disposable continuous glucose monitors (CGM)—the first CGMs tailored for Type 2 diabetes.
- The launch of Onduo, a joint venture created through Sanofi and Verily’s diabetes-focused collaboration
- An agreement with GSK to invest jointly in Galvani Bioelectronics to enable the research, development, and commercialization of bioelectronic medicines
- An agreement with Alcon, the eye care division of Novartis, on a smart lens program that includes projects to develop both a glucose sensing lens and an accommodating lens
- The establishment of Verb Surgical, a robotic surgery joint venture with J&J
Posted by Brian Otis, Chief Technical Officer, Verily